Next Article in Journal
Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
Next Article in Special Issue
Quantifying the Epithelial-to-Mesenchymal Transition (EMT) from Bench to Bedside
Previous Article in Journal
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
Previous Article in Special Issue
Single-Cell RNA-Seq Analysis Reveals the Acquisition of Cancer Stem Cell Traits and Increase of Cell–Cell Signaling during EMT Progression
 
 
Article

Article Versions Notes

Cancers 2022, 14(1), 209; https://doi.org/10.3390/cancers14010209
Action Date Notes Link
article xml file uploaded 1 January 2022 09:41 CET Original file -
article xml uploaded. 1 January 2022 09:41 CET Update -
article pdf uploaded. 1 January 2022 09:41 CET Version of Record https://www.mdpi.com/2072-6694/14/1/209/pdf-vor
article supplementary file uploaded. 1 January 2022 09:41 CET - https://www.mdpi.com/2072-6694/14/1/209#supplementary
article html file updated 1 January 2022 09:42 CET Original file -
article xml file uploaded 5 January 2022 07:10 CET Update -
article xml uploaded. 5 January 2022 07:10 CET Update https://www.mdpi.com/2072-6694/14/1/209/xml
article pdf uploaded. 5 January 2022 07:10 CET Updated version of record https://www.mdpi.com/2072-6694/14/1/209/pdf
article html file updated 5 January 2022 07:12 CET Update -
article html file updated 31 July 2022 01:39 CEST Update https://www.mdpi.com/2072-6694/14/1/209/html
Back to TopTop